Abstracts tagged "Psoriatic arthritis"

Abstract Number: 1249 • ACR Convergence 2024
Patient-Reported Outcomes in Inflammatory Arthritis: A Four-Year Retrospective Analysis via the PatientSpot Research Registry
Shilpa Venkatachalam¹, Kelly Gavigan², Erik Stone³, Angela Degrassi², Laura Stradford⁴, David Curtis², Esteban Rivera⁵ and Jeffrey Curtis⁶, ¹Global Healthy Living Foundation, New York, NY, ²Global Healthy Living Foundation, Upper Nyack, NY, ³Global Healthy Living Foundation, Upper Nyack, ⁴Global Healthy Living Foundation, Nyack, NY, ⁵Global Healthy Living Foundation, Long Island City, NY, ⁶University of Alabama at Birmingham, Hoover, AL
Background/Purpose: Understanding the impact of inflammatory arthritis from patients’ perspectives through patient-reported outcomes (PROs) data can provide valuable insights into outcomes prioritized by those living…
Abstract Number: 1465 • ACR Convergence 2024
The Use of Disease Activity Thresholds for the Psoriatic Arthritis Impact of Disease Questionnaire to Assess Patient Perceptions of Disease Burden in Patients with Early Oligoarticular Psoriatic Arthritis Treated with Apremilast in a Phase 4 Trial
Laure Gossec¹, Laura Coates², Dafna Gladman³, Alexis Ogdie⁴, Peter Nash⁵, Denis Poddubnyy⁶, Arthur Kavanaugh⁷, April Armstrong⁸, Carlo Selmi⁹, Ruben Queiro Silva¹⁰, Cynthia Deignan¹¹, Rebecca Wang¹¹, Jyotsna Reddy¹¹, Michele Brunori¹¹ and Philip Mease¹², ¹Sorbonne Université, Paris, France, ²University of Oxford, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom, ³University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁵School of Medicine, Griffith University, Sunshine Coast, Queensland, Australia, ⁶Charite-Universitatsmedizin Berlin, Berlin, Germany, ⁷University of California, San Diego, School of Medicine, La Jolla, CA, ⁸University of California Los Angeles, Los Angeles, CA, ⁹Department of Biomedical Sciences, Humanitas University, Rozzano, Italy, ¹⁰Rheumatology Division, Hospital Universitario Central de Asturias, Oviedo University School of Medicine, Oviedo, Spain, ¹¹Amgen Inc., Thousand Oaks, CA, ¹²Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA
Background/Purpose: Oligoarticular psoriatic arthritis (PsA, ≤4 joints affected) is common but understudied, as most clinical trials enroll patients (pts) with ≥3 swollen and tender joints.…
Abstract Number: 1883 • ACR Convergence 2024
Psoriatic Arthritis Flare Incidence, Definitions and Risk Factors: A Systematic Review
Batoul Hojeij¹, Gonul Hazal Koc², Jolanda Luime¹, Marijn Vis¹, Marc R. Kok³ and Ilja Tchetverikov⁴, ¹Erasmus MC, Rotterdam, Netherlands, ²Erasmus MC, Rotterdam, Zuid-Holland, Netherlands, ³Maasstad Hospital, Rotterdam, Netherlands, ⁴Albert Schweitzer Hospital, Dordrecht, Netherlands
Background/Purpose: Combined assessment of psoriatic arthritis (PsA) flare incidence and risk factors has not been conducted before, leading to challenges in effective flare management, especially…
Abstract Number: 2314 • ACR Convergence 2024
Serum Calprotectin (S100A8/9) and Complement Factor C3 as Potential Inflammatory Markers in Obese and “CRP Negative” Early PsA Patients: Data from a Multicenter METAPSA Cohort
Alla Ishchenko¹, Margot Van Mechelen², Sofia Pazmino³, Lies Storms⁴, Patrick Verschueren⁵, Rik Lories⁶ and Kurt de Vlam⁷, ¹UZ Gasthuisberg, Leuven, Belgium, ²Antwerp University Hospital, Belgium, Antwerp, Belgium, ³KU Leuven University, Leuven, Belgium, Leuven, Belgium, ⁴KU Leuven, Leuven, Belgium, ⁵Department of Rheumatology, University Hospital Leuven and KU Leuven, Leuven, Belgium, ⁶Laboratory of Tissue Homeostasis and Disease, Skeletal Biology and Engineering Research Center, Department of Development and Regeneration, KU Leuven, Leuven, Belgium, Leuven, Belgium, ⁷Department of Rheumatology, UZ Leuven, and Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, KU Leuven, Leuven, Belgium
Background/Purpose: Systemic inflammation is an integral part of psoriatic arthritis (PsA). Despite substantial inflammation in the affected tissues such as skin, entheses and joints, C-reactive…
Abstract Number: 2331 • ACR Convergence 2024
Assessment of the Likelihood of Joint Inflammation Recurrence in Previously Affected Joints During Psoriatic Arthritis Disease Course
Dafne Capelusnik¹, Ori Elkayam² and Mark Berman³, ¹Tel Aviv Sourasky Medical Center, Ramat Gan, Israel, ²Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ³Tel Aviv Sourasky Medical Center, Kefar sava, Israel
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory disease that can cause joint pain, swelling, and stiffness. Patients often experience flares followed by periods of remission.…
Abstract Number: 2351 • ACR Convergence 2024
Low Uveitis Rates in Patients with Axial Spondyloarthritis or Psoriatic Arthritis Treated with Bimekizumab: Long-Term Results from Phase 2b/3 Trials
Irene E. van der Horst-Bruinsma¹, Matthew A. Brown², Floris van Gaalen³, Nigil Haroon⁴, Lianne S Gensler⁵, Alexander Marten⁶, Myriam Manente⁷, George Stojan⁸, Thomas Vaux⁹, Katy White⁹, Atul Deodhar¹⁰ and Martin Rudwaleit¹¹, ¹Department of Rheumatology, Radboud University Medical Centre, Nijmegen, Netherlands, ²Genomics England, London, United Kingdom, ³LUMC, Leiden, Zuid-Holland, Netherlands, ⁴Department of Medicine/Rheumatology, University Health Network, Schroeder Arthritis Institute, University of Toronto, Toronto, ON, Canada, ⁵Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁶UCB Pharma, Monheim am Rhein, Germany, ⁷UCB Pharma, Braine-l'Alleud, Belgium, ⁸UCB Pharma, Atlanta, GA, ⁹UCB Pharma, Slough, United Kingdom, ¹⁰Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ¹¹University of Bielefeld, Klinikum Bielefeld, Bielefeld, Germany
Background/Purpose: Acute anterior uveitis (‘uveitis’) is a common extra-musculoskeletal manifestation in patients (pts) with spondyloarthritis (SpA), and incidence varies with SpA type and disease duration.1,2,3…
Abstract Number: 2584 • ACR Convergence 2024
Zasocitinib (TAK-279), an Oral, Selective Tyrosine Kinase 2 Inhibitor: Achievement of Remission and Additional Improvements in Disease Activity in Patients with Psoriatic Arthritis Enrolled in a Phase 2b Trial
Philip Mease¹, Alan Kivitz², Elena Muensterman³, Apinya Lertratanakul⁴, Ting Hong⁴, Jingjing Chen⁴, Ejim Mark⁵ and Xenofon Baraliakos⁶, ¹Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, ²Altoona Center for Clinical Research, Duncansville, PA, ³Takeda Development Center Americas, Cambridge, MA, ⁴Takeda Development Center Americas, Inc., Cambridge, MA, ⁵Takeda Development Center Americas Inc., Cambridge, ⁶Rheumazentrum Ruhrgebiet Herne, and Ruhr-University Bochum, Bochum, Germany
Background/Purpose: Zasocitinib (TAK-279) is an oral, selective TYK2 inhibitor under investigation for the treatment of immune-mediated inflammatory diseases including psoriatic arthritis (PsA). In a phase…
Abstract Number: L12 • ACR Convergence 2023
Efficacy and Safety Outcomes of TAK-279, a Selective Oral Tyrosine Kinase 2 (TYK2) Inhibitor, from a Randomized, Double-blind, Placebo-controlled Phase 2b Trial in Patients with Active Psoriatic Arthritis
Alan Kivitz¹, Elena Tomaselli Muensterman², Arthur Kavanaugh³, Désirée van der Heijde⁴, Piotr A. Klimiuk⁵, Guillermo Valenzuela⁶, Eva Dokoupilova⁷, Gabrielle Poirier⁸, Bhaskar Srivastava⁸, Sue Dasen⁸, Xinyan Zhang⁸, Mona Trivedi², Haoling Holly Weng⁹, Ting Hong¹⁰, Peter Pothula¹⁰ and Xenofon Baraliakos¹¹, ¹Altoona Center for Clinical Research, Duncansville, PA, ²Takeda Development Center Americas, Inc., Cambridge, MA, ³Division of Rheumatology, Allergy & Immunology, University of California San Diego Medical School, San Diego, CA, ⁴Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, ⁵Department of Rheumatology and Internal Diseases, Medical University of Bialystok and Inter Clinic Piotr Adrian Klimiuk, Białystok, Poland, ⁶Integral Rheumatology & Immunology Specialists, Plantation, FL, ⁷Department of Pharmaceutical Technology, Faculty of Pharmacy, Masaryk University and MEDICAL PLUS, s.r.o., Brno and Uherské Hradiště, Czech Republic, ⁸Nimbus Discovery, Inc., Boston, MA, ⁹HW MedAdvice LLC, San Diego, CA, ¹⁰Takeda Development Center Americas, Inc., Boston, MA, ¹¹Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Bochum, Germany
Background/Purpose: TYK2 mediates signaling by key cytokines involved in the pathogenesis of immune-mediated inflammatory diseases such as psoriatic arthritis (PsA) and psoriasis (PsO). TAK-279 is…
Abstract Number: 0062 • ACR Convergence 2023
Differential Metabolic Profiles, Activation and Circadian Dynamics in Rheumatoid Arthritis and Psoriatic Arthritis Circulatory Monocytes
Alyssa Gilmore¹, Success Amaechi², Megan Hanlon³, Dumitru Anton⁴, Carl Orr⁵, Viviana Marzaioli⁶, Douglas Veale⁷ and Ursula Fearon¹, ¹Trinity College Dublin, Dublin, Ireland, ²Trinity College Dublin, Mullingar, Ireland, ³Molecular Rheumatology, Dublin, Ireland, ⁴Molecular Rheumatology Department, Trinity Biomedical Sciences Institute, Trinity College Dublin, EULAR Centre for Arthritis and Rheumatic Diseases, St Vincent University Hospital, University College Dublin, Dublin, Ireland, ⁵Saint Vincent's University Hospital, Dublin, Ireland, ⁶Trinity College Dublin and University College Dublin, Dublin, Ireland, ⁷St.Vincent's University Hosp, Dublin, Ireland
Background/Purpose: While Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA) share many features, they are distinct in clinical presentation and molecular profile. As monocytes are crucial…
Abstract Number: 0487 • ACR Convergence 2023
A Comparative Study of Serositis Between Inpatients with Psoriatic Arthritis and Rheumatoid Arthritis
Ashmia Saif¹, Priyanka Dongare², Meghan Beard³, Yunhan Liao⁴, Xiaoyue Zhang⁴, Qingping Yao⁵ and Asha Patnaik⁶, ¹Stony Brook University Hospital, Syosset, NY, ²Stony Brook University Hospital, Highland, NY, ³Stony Brook Southampton, Moriches, NY, ⁴Biostatistical Consulting Core - Renaissance School of Medicine at Stony Brook University, Stony Brook, NY, ⁵Stony Brook University, Stony Brook, NY, ⁶Stony Brook University Medical Center, East Setauket, NY
Background/Purpose: Autoimmune diseases such as rheumatoid arthritis (RA) and psoriatic arthritis (PsA) can causes erositis including pericarditis and pleuritis. However, the rate of serositis in…
Abstract Number: 0503 • ACR Convergence 2023
Spinal Inflammation a Dominant Pathology in Psoriatic Arthritis: Characterization and Quantification by In-Vivo 18F-FDG Total-Body PET/CT Imaging
Siba Raychaudhuri¹, Yasser Abdelhafez², Dario Mazza², Smriti K Raychaudhuri³ and Abhijit Chaudhari⁴, ¹UC Davis, School of Medicine/ VA Medical Center, Sacramento, Davis, CA, ²University of California Davis, Sacramento, CA, ³VA Sacramento Medical Center, Mather, CA, ⁴UC Davis School of Medicine, Sacramento, CA
Background/Purpose: Right and Moll recognized the presence of spinal inflammation/axial disease in psoriatic arthritis (PsA) in their seminal work in 1973. The prevalence of axial…
Abstract Number: 0778 • ACR Convergence 2023
The Effect of Probiotic Modulation of Enteral Dysbiosis on Disease Activity in Patients with Psoriatic Arthritis – A Randomized Controlled Trial
Anirudh Subramanian Muralikrishnan¹, Barbara Dreo², Angelika Lackner¹, Rusmir Husic³, Florentine Moazedi-Fuerst³, Josef Hermann⁴, Philipp Bosch¹, Johannes Fessler¹, Jens Thiel⁵ and Martin Stradner¹, ¹Medical University of Graz, Graz, Austria, ²Division of Rheumatology and Immunology, Medical University of Graz, Graz, Austria, ³Meduni Graz, Graz, Austria, ⁴Division of Rheumatology and Immunology, Department of Internal Medicine, Medical University Graz, Graz, Austria, ⁵University Hospital Freiburg, Freiburg, Germany
Background/Purpose: Psoriatic Arthritis (PsA) is a painful disease of the joints and spine. Recent studies have described enteric dysbiosis as a possible pathological mechanism in…
Abstract Number: 1388 • ACR Convergence 2023
Pain Mechanisms in Psoriatic Arthritis: Differentiating Inflammation Related Pain in Enthesitis Using Ultrasound, in Comparison to Functional MRI
Ummugulsum Gazel¹, Kristen Noges², Burak Ayan², Gizem Ayan³, Olivier Brown¹, Andra Smith¹ and sibel aydin⁴, ¹University of Ottawa, Ottawa, ON, Canada, ²University of Ottawa, Rheumatology, Ottawa, ON, Canada, ³Hacettepe University Faculty of Medicine Division of Rheumatology, Ankara, Turkey, ⁴University of Ottawa - Ottawa, Ottawa, ON, Canada
Background/Purpose: Approximately 50% of PsA patients have persistent pain despite a well‐controlled inflammatory state, which has been attributed to non‐nociceptive pain and central sensitization. Enthesitis…
Abstract Number: 1426 • ACR Convergence 2023
Distinct Treatment Response Trajectories in Patients with Psoriatic Arthritis Receiving Tofacitinib
Dafna Gladman¹, William R Tillett², David Gruben³, Laura Coates⁴, Stefanie Hahne⁵ and Mikhail Volkov⁶, ¹Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, ²Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ³Pfizer Inc., Groton, CT, ⁴University of Oxford, Oxford, United Kingdom, ⁵Pfizer Pharma GmbH, Berlin, Germany, ⁶Pfizer BV, Capelle aan den IJssel, Netherlands
Background/Purpose: PsA is a heterogeneous disease, and identifying clinical phenotypes may assist clinical decision making. Patients (pts) treated with advanced therapies demonstrate varying treatment responses.…
Abstract Number: 1640 • ACR Convergence 2023
Psoriatic Disease Associated with Neuroconnectivity Alterations in the Default Mode Network
Rebecca Haberman¹, Sydney Catron¹, Yu Veronica Sui¹, Sarah Moussavi¹, Soumya Reddy², Eileen Lydon³, Andrea Neimann¹, Alexis R Ogdie⁴, Mariana Lazar¹ and Jose Scher⁵, ¹NYU Grossman School of Medicine, New York, NY, ²NYU School of Medicine, New York, NY, ³New York University, New York, NY, ⁴University of Pennsylvania, Philadelphia, PA, ⁵New York University School of Medicine, New York, NY
Background/Purpose: Despite significant advances in psoriatic disease (PsD) therapeutics, treatment response remains suboptimal. Even in patients with psoriatic arthritis (PSA) that achieve seemingly controlled inflammation,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].